Methylprednisolon

ApprovedSmall molecule

SSisli Hamidiye Etfal Training and Research Hospital

Methylprednisolon is one of 36 small molecule programs targeting Plantar Fasciitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Plantar FasciitisActive, not recruiting

VertigoActive, not recruiting

Plantar FasciitisApproved

Active, not recruiting

VertigoPhase 3

Active, not recruiting

Competition

Competitive Landscape

39 competitors in Plantar Fasciitis

#DrugCompanyPhaseTrials

Medrol

Pfizer

Approved

1 2

Marcaine

Plasma

1 4

Xeomin

MMerz Therapeutics GmbH

Approved

1 5

Botox

RRevance Therapeutics, Inc.

Phase 3

1 6

Decadron

AAspen Global Incorporated

Phase 2

2 7

Methylprednisolon

SSisli Hamidiye Etfal Training and Research Hospital

Approved

1 8

Xiaflex

GGrupo Espanol de Tumores Neuroendocrinos

Phase 2

1 9

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 2

—10

Naropin

FFresenius Kabi Oncology Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Vertigo

NCT05851508

Clinical

Trials by Indication[1]

Vertigo1 trial

The Effecttiveness of Intratympanic Methylprednisolon Injections Compared to Placebo in the Treatment of Vertigo Attacks in Meniere's Disease

Recruiting·LLeiden University Medical Center·Phase 3·NCT05851508·148 enrolled

Plantar Fasciitis1 trial

Plantar Fasciitis, Operation or Conservative Treatment

Completed·—·Phase 4·NCT02448316·30 enrolled